GC Biopharma Corp.

A006280

KR7006280002

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 2025-01-24			5-day change	1st Jan Change
139,300.00 ^KRW	-1.28%		-4.85%	-22.40%

Jan. 13	Advanced Infusion Care now offers GC Biopharma?s ALYGLO?	CI
Dec. 10	GC Biopharma Corp. agreed to acquire 5.30% stake in 4Human Life No. 1 Private Equity Joint Venture Company for KRW 82.3 billion.	CI

GC Biopharma USA Names Sean Zam as Head of Sales and Marketing

November 22, 2024 at 02:53 pm EST

GC Biopharma USA has announced the appointment of industry veteran, Sean Zam, to its senior leadership team as Head of Sales and Marketing. He comes to GC Biopharma USA with a wealth of experience in the pharmaceutical industry, including extensive experience in plasma therapeutics. Sean has a proven track record of growing business and building lasting partnerships for companies such as Grifols, AstraZeneca, and Pfizer.

Stocks mentioned in the article

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
GC BIOPHARMA CORP.	139,300.00KRW	-1.28%	-4.85%	1.11B
ASTRAZENECA PLC	11,050.00GBX	+0.04%	+1.02%	214B
PFIZER, INC.	26.09USD	+0.31%	-0.80%	148B
GRIFOLS, S.A.	8.616EUR	+1.20%	-3.08%	5.67B

Latest news about GC Biopharma Corp.

Advanced Infusion Care now offers GC Biopharma?s ALYGLO?	Jan. 13	CI
GC Biopharma Corp. agreed to acquire 5.30% stake in 4Human Life No. 1 Private Equity Joint Venture Company for KRW 82.3 billion.	Dec. 10	CI
GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment	Nov. 25	CI
GC Biopharma, Kanaph Partner on Bispecific ADC Development	Nov. 24	MT
GC Biopharma USA Names Sean Zam as Head of Sales and Marketing	Nov. 22	CI
GC Biopharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 14	CI
GC Biopharma and Novelty Nobility Enter into Joint Research and Development Agreement for Geographic Atrophy Therapies	24-10-28	CI
GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA	24-09-03	CI
GC Biopharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-14	CI
Korea's GC Group to Sell Hong Kong Unit to CR Pharmaceutical	24-07-19	MT
GC Biopharma Teams Up with US Pharmacy Benefit Manager for Immunodeficiency Treatment	24-07-03	MT
FDA Grants Fast Track Designation to GCBP and Novel Pharma's GC1130A	24-06-10	CI
Gc Biopharma and Novel Pharma Announce Sanfilippo Syndrome Treatment Obtains FDA IND Approval	24-05-20	CI
GC Biopharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	24-05-16	CI
Green Cross Widens Q1 Loss, Sales Inch Up 2%	24-05-03	MT
GC Biopharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	24-03-20	CI
GC Biopharma Corp. Announces US FDA Approval for ALYGLO (Immune Globulin Intravenous, Human-Stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)	23-12-17	CI
GC Biopharma Establishes mRNA Production Facility in Hwasun, Korea	23-12-01	CI
GC Biopharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-11-14	CI
GC Biopharma Applies for MFDS Approval	23-11-05	CI
Immetas Therapeutics and GC Biopharma Announces Research Collaboration to Discover and Develop mRNA Therapeutics to Treat Autoimmune Diseases	23-10-12	CI
GC Biopharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Green Cross's Net Income Plunges in Q2	23-08-02	MT
GC Biopharma's "GC FLU" Obtains Vaccine Approval in Egypt	23-07-21	CI
GC Biopharma Receives a Business License for the Construction of a Plasma Fractionation Plant and Technology Transfer in Indonesia	23-06-01	CI

Chart GC Biopharma Corp.

Duration

Period

A006280: Dynamic Chart

Company Profile

GC Biopharma Corp is a Korea-based company primarily engaged in the manufacturing and sales of pharmaceuticals. The Company operates its business through three segments. The Pharmaceuticals Manufacturing and Sale segment is primarily engaged in the production of pharmaceuticals, including blood products, general products, vaccines, OTC drugs, diagnostic reagents, placental injections, cell therapy products, vaccine fertilized eggs, and blood diagnostic products. The Diagnostic and Analysis segment is primarily engaged in blood diagnostics and genetic analysis. The Other segment is primarily engaged in other business, such as livestock farming.

Employees

2,009

Sector

Pharmaceuticals

Calendar

2025-02-17 - Q4 2024 Earnings Release (Projected)

More about the company